Sanara MedTech (SMTI) Stock Price, News & Analysis

Company Overview

Sanara MedTech (NASDAQ:SMTI) is a regenerative medicine company specializing in the development, manufacturing and commercialization of cryopreserved human placental and cellular-based allograft products. The company’s portfolio is designed to support tissue repair and regeneration across multiple medical specialties, including orthopedics, sports medicine, chronic wound care, ophthalmology and aesthetic surgery. Sanara’s allografts are processed under strict tissue banking standards to preserve native extracellular matrix components and functional growth factors.

The company’s flagship products include dCELL Surgical Matrix and dCELL Skin Matrix, which are used by surgeons and clinicians to promote healing in complex soft tissue and skin injuries. Sanara’s proprietary processing methods ensure high viability of critical bioactive elements while meeting FDA tissue establishment registration requirements. Research and development efforts focus on enhancing product performance, expanding indications and advancing next-generation cellular therapies in collaboration with leading academic and clinical partners.

Headquartered in Austin, Texas, Sanara MedTech operates a state-of-the-art manufacturing facility that complies with U.S. Food and Drug Administration and European regulatory standards. Through a network of authorized distributors, the company serves hospitals, outpatient surgery centers, physician offices and specialized wound care clinics in North America, Europe and select international markets. Sanara’s customer support infrastructure includes clinical training, technical assistance and educational programs to optimize product adoption and patient outcomes.

Since its inception, Sanara MedTech has grown by combining organic innovation with strategic acquisitions to build a comprehensive regenerative medicine platform. The leadership team comprises experienced executives with deep backgrounds in tissue banking, medical devices and biopharmaceutical operations. Under their guidance, Sanara continues to invest in research, regulatory compliance and quality systems to drive sustainable growth and elevate standards of care in regenerative medicine worldwide.

Key Stats

• Today's Range: $29.06 to $30.49
• 50-Day Range: $27.28 to $35.10
• 52-Week Range: $25.86 to $39.08
• Volume: 41,270 shs
• Average Volume: 29,155 shs
• Market Capitalization: $258.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.50
• Consensus Rating: Buy

Sanara MedTech Stock Analysis - MarketRank™

Sanara MedTech scored higher than 44% of companies evaluated by MarketBeat, and ranked 662nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sanara MedTech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sanara MedTech are expected to grow in the coming year, from ($1.10) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanara MedTech is -21.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanara MedTech is -21.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sanara MedTech has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.66% of the float of Sanara MedTech has been sold short.

Short Interest Ratio / Days to Cover

Sanara MedTech has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Sanara MedTech has recently increased by 8.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sanara MedTech does not currently pay a dividend.

Dividend Growth

Sanara MedTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.66% of the float of Sanara MedTech has been sold short.

Short Interest Ratio / Days to Cover

Sanara MedTech has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Sanara MedTech has recently increased by 8.62%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Sanara MedTech has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sanara MedTech this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanara MedTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.60% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.10% of the stock of Sanara MedTech is held by institutions.

SMTI Stock Analysis - Frequently Asked Questions

How have SMTI shares performed this year?

Sanara MedTech's stock was trading at $33.20 at the start of the year. Since then, SMTI shares have decreased by 12.5% and is now trading at $29.06.

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) issued its earnings results on Wednesday, May, 14th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.10. The business earned $23.43 million during the quarter, compared to the consensus estimate of $23.48 million. Sanara MedTech had a negative trailing twelve-month return on equity of 29.22% and a negative net margin of 12.48%.
Read the conference call transcript.

How do I buy shares of Sanara MedTech?

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SMTI
• CIK: 714256
• Web: www.wndm.com
• Phone: (817) 529-2300
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sanara MedTech: $49.50
• High Price Target: $53.00
• Low Price Target: $46.00
• Potential Upside/Downside: +70.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.66 million
• Net Margins: -12.48%
• Pretax Margin: -12.71%
• Return on Equity: -29.22%
• Return on Assets: -13.20%

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 2.77
• Quick Ratio: 2.54

Sales & Book Value

• Annual Sales: $91.57 million
• Price / Sales: 2.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.45 per share
• Price / Book: 6.53

Miscellaneous

• Outstanding Shares: 8,888,000
• Free Float: 5,102,000
• Market Cap: $258.29 million
• Optionable: Not Optionable
• Beta: 1.30